Your search for major depressive disorder returned 77 results

Researchers conducted a phase 2 trial to assess the safety and efficacy of single-dose psilocybin treatment for major depressive disorder.

Researchers investigated the all-cause risk for mortality in patients with major depressive disorder exhibiting suicidal behavior.

Researchers evaluated the risk for major depressive disorder among patients with HIV infection.

A study was conducted to determine the effect of mental health disorders on postoperative outcomes following EVAR in patients who are veterans.

Some men have said that honest communication and community-based approaches make them more like to engage in mental health care.

Researchers searched for protective effects in gut microbiota from the pathogenesis of major depressive disorder.

Researchers assessed characteristics and correlates of metabolic syndrome in adolescents with major depressive disorder or bipolar disorder depression.

Researchers evaluated the efficacy of dextromorphan-bupropion among patients with major depressive disorder and comorbid anxiety.

Whether major depressive disorder is a comorbidity of bipolar disorder isn’t really known. Researchers built a predictive model of major depressive disorder to bipolar disorder conversion and with the Observational Medical Outcomes Partnership validated the results across a multi-national network of patient databases.

Investigators report the findings from a study assessing the impact of insomnia on clinical outcomes in patients with major depressive disorder.

The researchers sought to examine whether inflammation and white matter microstructure play a role in treatment response in major depressive disorder.

Researchers seek to evaluate whether trauma-focused therapy adjunctive to treatment as usual (TAU) leads to a greater reduction of depressive symptoms posttreatment vs TAU exclusively in patients with major depressive disorder with childhood trauma.

Researchers compared the white matter networks of patients with remitted major depressive disorder and remitted bipolar disorder to find disease-specific alterations.

For this study, community-dwelling adults were evaluated for major depressive disorder, generalized anxiety disorder, and global sleep quality over an 18 year period.

Investigators searched publication databases for randomized controlled trials evaluating cognitive training and remediation interventions among patients with MDD.

Outpatients were recruited at the Instituto Nacional de Psiquiatía (National Institute of Psychiatry) in Mexico and were evaluated for alcohol dependence and major depressive disorder.

Patients with somatoform disorders, major depressive disorder, and healthy controls were recruited between 2016 and 2017 at the Ambulante Psychosoziale Rehabilitation in Austria and Schoen Clinic Roseneck in Germany.

The researchers of this study explored the impact of a blended approach (bCBT) that included both face-to-face CBT and iCBT on patients with major depressive disorder and insomnia.

Investigators conducted a systematic review of studies published between January 1, 2020 and January 29, 2021 that estimated the prevalence of major depressive disorder and anxiety disorders during the COVID-19 pandemic.

Investigators sourced data for this study from the Stockholm Major Depressive Disorder Cohort. Between 2010 and 2018, all patients in the Stockholm region who met the criteria for MDD were enrolled in the cohort.

Patients with treatment-resistant major depressive disorder or bipolar disorder without psychotic symptoms received intravenous infusions of 0.5 mg/kg ketamine 3 times per week for 2 weeks.

Researchers explored the neurobiology related to reward-based reinforcement learning and psychomotor retardation in patients in remission from MDD.

Researchers examined correlations between suicidal ideation and suicide attempt history in patients with treatment-resistant depression following ketamine infusion.

To learn more about the impact of depression therapy on anxiety symptoms, researchers conducted a randomized controlled clinical trial with teenagers to compare the results of personalized depression therapy to a program that does not match their risk factors.

Researchers assessed whether clinical severity and instability, during a 2-month period, were predictors of later risk for psychiatric hospitalization within the next 6 months.

Researchers examined the effect of neuropeptides orexin-A, ghrelin, and neuropeptide Y on hypersomnia and hyperphagia. Both symptoms are more common in people with bipolar disorder.

In a recent survey, more than half the college students with ADHD had at least 1 psychiatric disorder. The recent WHO World Mental Health Survey of college students assessed comorbidities in more than 15,000 college freshmen across 9 countries.

Data for this study were sourced from 4 active treatment arms of 4 randomized, controlled trials conducted by the National Institutes of Health in the United States between 2006 and 2018.

Patients who had treatment-naïve MDD were recruited in the US between 2007 and 2013 for the Predictors of Remission in Depression to Individual and Combined Treatments (PReDICT) study.

A cross-sectional family study sought to determine if parents’ transmission of anxiety is sex specific.